Introduction
Materials and methods
Patients and diagnosis
Data extraction
Histologic analysis
In situ hybridization
Immunohistochemistry
Statistical analysis
Results
Clinical features of ENKTL
Patient no. | Age | Sex | Primary sites | Ann Arbor stage | LDH level | B symptoms | IPI | Therapy | Response to treatment | LMP1 expression (IHS) | LMP2A expression (IHS) |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 36 | M | Nasal cavity | II | Normal | Positive | LI | CHOP + FLAG | PR | 6 | 6 |
2 | 36 | M | Oropharynx | III | High | Positive | HI | CHOP | PR | 4 | 2 |
3 | 57 | M | Nasal cavity | II | Normal | Negative | HI | Surgery + CHOP | CR | 2 | 1 |
4 | 55 | M | Larynx | I | Normal | Positive | LI | Surgery + CHOP | PR | 8 | 1 |
5 | 49 | F | Nasal cavity | II | High | Negative | L | Surgery | NR | 1 | 4 |
6 | 51 | M | Nasal cavity | I | High | Negative | LI | CHOP + Radiotherapy | PR | 2 | 1 |
7 | 67 | M | Nasal cavity | II | Normal | Positive | HI | CHOP + GDP + CVAD | CR | 9 | 4 |
8 | 25 | M | Oropharynx, palate | II | Normal | Negative | L | CHOPE + ICE + Radiotherapy | CR | 1 | 9 |
9 | 71 | M | Nasal cavity | I | High | Positive | LI | CHOP + SMILE | CR | 4 | 2 |
10 | 36 | M | Nasal cavity | II | Normal | Negative | L | CHOP | PR | 6 | 1 |
11 | 63 | M | Nasal cavity | I | Normal | Negative | L | CEVP + Radiotherapy | PR | 2 | 1 |
12 | 56 | M | Nasal cavity | II | Normal | Positive | LI | Surgery + CHOP | PR | 3 | 2 |
13 | 66 | F | Larynx | II | High | Positive | HI | Surgery | CR | 6 | 8 |
14 | 47 | M | Nasopharynx | I | Normal | Negative | L | VEPA + Radiotherapy | CR | 8 | 1 |
15 | 51 | F | Nasal cavity | III | Normal | Positive | HI | DICE + SMILE | PR | 9 | 9 |
16 | 27 | M | Nasal cavity | II | Normal | Negative | LI | Surgery + CHOP | CR | 3 | 6 |
Expression of LMP1 and LMP2A in ENKTL
Correlation between LMP1 and LMP2A expression with clinicopathological parameters of ENKTL
Groups | No. | LMP1 expression | p value | LMP2A expression | p value | ||
---|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | ||||
Gender | |||||||
Male | 13 | 7 | 6 | 0.687 | 4 | 9 | 0.029* |
Female | 3 | 2 | 1 | 3 | 0 | ||
Age (years) | |||||||
≤40 y | 5 | 3 | 2 | 0.838 | 3 | 2 | 0.377 |
>40 y | 11 | 6 | 5 | 4 | 7 | ||
Ann Arbor Stage | |||||||
I-II | 14 | 7 | 7 | 0.182 | 6 | 8 | 0.849 |
III-IV | 2 | 2 | 0 | 1 | 1 | ||
LDH level | |||||||
High | 5 | 3 | 2 | 0.838 | 2 | 3 | 0.838 |
Normal | 11 | 6 | 5 | 5 | 6 | ||
B symptoms | |||||||
Positive | 8 | 7 | 1 | 0.012* | 4 | 4 | 0.614 |
Negative | 8 | 2 | 6 | 3 | 5 | ||
IPI | |||||||
Low/Low-intermediate | 11 | 5 | 6 | 0.197 | 4 | 7 | 0.377 |
High-intermediate/High | 5 | 4 | 1 | 3 | 2 | ||
Response to treatment | |||||||
Complete remission | 7 | 4 | 3 | 0.493 | 4 | 3 | 0.319 |
Partial remission | 8 | 5 | 3 | 2 | 6 | ||
No response | 1 | 0 | 1 | 1 | 0 | ||
Prognosis | |||||||
Live | 7 | 2 | 5 | 0.049* | 1 | 6 | 0.036* |
Dead | 9 | 7 | 2 | 6 | 3 |
Patients’ survival
Variable | p value |
---|---|
Gender | |
Male versus Female | 0.0658 |
Age (years) | |
≤40y versus >40y | 0.8679 |
Ann Arbor Stage | |
Stage I, II versus Stage III, IV | 0.4129 |
LDH level | |
High versus Normal | 0.7703 |
B symptoms | |
Positive versus Negative | 0.0180* |
IPI | |
L/LI versus HI/H | 0.5418 |
Treatment | |
Single therapy versus Combined therapy | 0.0082* |
LMP1 expression | |
Positive versus Negative | 0.0201* |
LMP2A expression | |
Positive versus Negative | 0.0487* |